<DOC>
	<DOCNO>NCT01189487</DOCNO>
	<brief_summary>Unasyn-S 12g/day ( 3 g four time day ) commonly use dosage depend severity US , EU , China , Taiwan Korea 20 year , however , Unasyn-S 12g/day yet approve Japan . The purpose trial evaluate clinical efficacy safety Japanese adult subject community acquire pneumonia receive ampicillin sodium/sulbactam sodium , 12g/day ( 3 g four time day ) IV .</brief_summary>
	<brief_title>The Study Unasyn-S 12g/Day Community Acquired Pneumonia ( CAP )</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Sultamicillin</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<criteria>16 year age old . Patients diagnose moderate severe community acquire pneumonia require initial intravenous therapy hospitalization . Known suspected hypersensitivity intolerance ampicillin sodium/sulbactam sodium , penicillin , cephems . Hepatic dysfunction [ Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , total bilirubin &gt; 3 time upper limit normal range value ] . Severe renal dysfunction ( creatinine clearance &lt; 30 ml/min ) . Severe underlying disease ; patient drug clinical evaluation difficult confounding disease .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>ampicillin sodium/sulbactam sodium</keyword>
	<keyword>Unasyn-S</keyword>
	<keyword>community acquire pneumonia</keyword>
	<keyword>bacterial pneumonia</keyword>
</DOC>